Xilio Therapeutics, Inc. (XLO) — Financial statements
Income statement, balance sheet, and cash flow for Xilio Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 44↑589.9% | 6 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 2 | 0.00 | 0.00 | 0.00↓100.0% | 1 | |
| Gross Profit | 42↑565.6% | 6 | 0.00 | 0.00↑100.0% | -1 | |
| Operating Expenses | ||||||
| R&D Expenses | 56↑36.0% | 41↓21.0% | 52↓11.9% | 59↑15.7% | 51 | |
| General & Administrative Expenses | 30↑19.9% | 25↓8.2% | 27↓9.9% | 30 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 30↑19.9% | 25↓8.2% | 27↓9.9% | 30↑34.0% | 22 | |
| Other Expenses | -2↓264.5% | 0.94 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 84↑25.8% | 67↓15.4% | 79↓11.2% | 89↑21.2% | 74 | |
| Total Costs & Expenses | 86↑28.1% | 67↓15.4% | 79↓11.2% | 89↑18.8% | 75 | |
| Operating Results | ||||||
| Operating Income | -42↑30.7% | -61↑23.4% | -79↑11.2% | -89↓18.8% | -75 | |
| Depreciation & Amortization | 2↓6.3% | 2↓13.5% | 2↑2.9% | 2↑23.2% | 1 | |
| EBITDA | -40↑30.3% | -58↑24.9% | -77↑11.5% | -87↓18.5% | -74 | |
| EBIT | -42↑29.6% | -60↑24.6% | -79↑11.2% | -89↓18.5% | -75 | |
| Interest & Other Income | ||||||
| Net Interest Income | 3↑3500.0% | -0.10 | 0.00 | 0.00↑100.0% | -0.60 | |
| Interest Income | 3 | 0.00 | 0.00 | 0.00↓100.0% | 0.00 | |
| Interest Expense | 0.00↓100.0% | 0.10 | 0.00 | 0.00↓100.0% | 0.60 | |
| Non-Operating Income | 0.00↑100.0% | -0.94 | 0.00 | 0.00↓100.0% | 0.16 | |
| Other Income / Expenses | 7↑196.7% | 2↓14.2% | 3↑194.4% | 0.93↑222.6% | -0.76 | |
| Income Before Tax | -35↑39.8% | -58↑23.8% | -76↑13.4% | -88↓16.4% | -76 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -35↑39.8% | -58↑23.8% | -76↑13.4% | -88↓16.4% | -76 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -35↑39.8% | -58↑23.8% | -76↑13.4% | -88↓16.4% | -76 | |
| Bottom-Line Net Income | -35↑39.8% | -58↑23.8% | -76↑13.4% | -88↓16.4% | -76 | |
| EPS (Basic) | -4.19↑72.5% | -15.26↑60.8% | -38.92↑13.7% | -45.08↑76.2% | -189.28 | |
| EPS (Diluted) | -4.19↑72.5% | -15.26↑60.8% | -38.92↑13.7% | -45.08↑76.2% | -189.28 | |
| Weighted Average Shares | 84↑2087.0% | 4↑94.6% | 2↑0.4% | 2↑388.6% | 0.40 | |
| Weighted Average Diluted Shares | 84↑2087.0% | 4↑94.6% | 2↑0.4% | 2↑388.6% | 0.40 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.